

# Summary of Product Characteristics

## 1 NAME OF THE MEDICINAL PRODUCT

Clariscan 279.32 mg/ml solution for injection in pre-filled syringe

## 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

1 mL solution for injection contains 279.32 mg gadoteric acid\* (as gadoterate meglumine) equivalent to 0.5 mmol

Tetraxetan (DOTA) 202.46 mg

Gadolinium oxide 90.62 mg

\* Gadoteric acid: gadolinium complex with 1,4,7,10 tetraazacyclododecane N,N',N'',N''' tetraacetic acid (tetraxetan (DOTA))

For the full list of excipients, see section 6.1.

## 3 PHARMACEUTICAL FORM

Solution for injection in prefilled syringe

Clear, colourless to slightly yellow solution

|                               |  |
|-------------------------------|--|
| Contrast medium concentration | 279.32 mg/mL equivalent to 0.5 mmol/mL |
| Osmolality at 37 °C           | 1350 mOsm.kg <sup>-1</sup>             |
| Viscosity at 20 °C            | 3.0 mPa.s                              |
| Viscosity at 37 °C            | 2.1 mPa.s                              |
| pH value                      | 6.5 – 8.0                              |

## 4 CLINICAL PARTICULARS

### 4.1 Therapeutic indications

This medicinal product is for diagnostic use only.

Clariscan should be used only when diagnostic information is essential and not available with unenhanced magnetic resonance imaging (MRI).

Clariscan is a contrast agent indicated for enhancement of the contrast in Magnetic Resonance Imaging for a better visualization/delineation.

Adult population and paediatric population (0-18 years):

- lesions of the brain, spine, and surrounding tissues
- whole body MRI (see section 4.2)

Use for whole body is not recommended in children under 6 months.

In adults only:

- lesions or stenoses of the non-coronary arteries (MR Angiography).

## 4.2 Posology and method of administration

This medicinal product should only be administered by trained healthcare professionals with technical expertise in performing and interpreting gadolinium enhanced MRI.

### **Posology**

The lowest dose that provides sufficient enhancement for diagnostic purposes should be used. The dose should be calculated based on the patient's body weight, and should not exceed the recommended dose per kilogram of body weight detailed in this section.

### **Adults**

#### MRI of brain and spine

The recommended dose is 0.1 mmol/kg BW, i.e. 0.2 mL/kg BW. In patients with brain tumours, an additional dose of 0.2 mmol/kg BW, i.e. 0.4 mL/kg BW, may improve tumour characterisation and facilitate therapeutic decision making.

#### Whole body MRI (including lesions of the liver, kidneys, pancreas, pelvis, lungs, heart, breast, and musculoskeletal system)

The recommended dose is 0.1 mmol/kg BW, i.e. 0.2 mL/kg BW to provide diagnostically adequate contrast.

#### *For angiography:*

The recommended dose for intravenous injection is 0.1 mmol/kg BW, i.e. 0.2 mL/kg BW to provide diagnostically adequate contrast.

In exceptional circumstances (e.g. failure to gain satisfactory images of an extensive vascular territory) administration of a second consecutive injection of 0.1 mmol/kg BW, i.e. 0.2 mL/kg BW may be justified. However, if the use of 2 consecutive doses of Clariscan are anticipated prior to commencing angiography, the use of 0.05 mmol/kg BW (i.e. 0.1 mL/kg BW) for each dose may be of benefit, depending on the imaging equipment available.

### **Special populations**

#### Impaired renal function

The adult dose applies to patients with mild to moderate renal impairment ( $\text{GFR} \geq 30 \text{ mL/min/1.73m}^2$ ).

Clariscan should only be used in patients with severe renal impairment ( $\text{GFR} < 30 \text{ mL/min/1.73m}^2$ ) and in patients in the perioperative liver transplantation period after careful risk/benefit assessment and if the diagnostic information is essential and not available with non-contrast enhanced MRI (see section 4.4). If it is necessary to use Clariscan the dose should not exceed 0.1 mmol/kg body weight.

More than one dose should not be used during a scan. Because of the lack of information on repeated administration, Clariscan injections should not be repeated unless the interval between injections is at least 7 days.

#### Elderly (aged 65 years and above)

No dosage adjustment is considered necessary. Caution should be exercised in elderly patients (see section 4.4).

#### Impaired hepatic function

The adult dose applies to these patients. Caution is recommended, especially in the case of perioperative liver transplantation period (see above impaired renal function).

#### Paediatric population (aged 0-18 years)

*Encephalic and Spinal MRI, Whole body MRI:*

The recommended and maximum dose of Clariscan is 0.1 mmol/kg body weight. More than one dose should not be used during a scan.

Due to immature renal function in neonates up to 4 weeks of age and infants up to 1 year of age, Clariscan should only be used in these patients after careful consideration, at a dose not exceeding 0.1 mmol/kg body weight. More than one dose

should not be used during a scan. Because of the lack of information on repeated administration, Clariscan injections should not be repeated unless the interval between injections is at least 7 days.

Use for whole body MRI is not recommended in children less than 6 months of age.

#### *Angiography:*

Clariscan is not recommended for angiography in children under 18 years of age due to insufficient data on its efficacy and safety in this indication (see section 4.4).

### **Method of administration**

The product is indicated for intravenous administration only.

Infusion rate: 3-5 mL/min (higher infusion rates up to 120 mL/min, i.e. 2 mL/sec, may be used for angiographic procedures).

For instructions on preparation and disposal, see section 6.6.

Intravascular administration of contrast media should, if possible, be done with the patient lying down. After the administration, the patient should be kept under observation for at least half an hour, since experience shows that the majority of undesirable effects occur within this time.

For single patient use only, any unused solution should be discarded.

#### Paediatric population (0-18 years)

Depending on the amount of Clariscan to be given to the child, it is preferable to use Clariscan vials with a single use syringe of a volume adapted to this amount in order to have a better precision of the injected volume.

In neonates and infants, the required dose should be administered by hand.

#### Image acquisition

Contrast enhanced MRI may be initiated immediately after administration of the agent. Optimal imaging: within 45 minutes after injection. Optimal image sequence: T1-weighted

### **4.3 Contraindications**

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

### **4.4 Special warnings and precautions for use**

Gadoteric acid must not be used intrathecally. Serious, life-threatening and fatal cases, primarily with neurological reactions (e.g. coma, encephalopathy, seizures), have been reported with intrathecal use. Clariscan is administered strictly by intravenous injection only. Extravasation local intolerance reactions may be observed, necessitating short term local treatment.

Appropriate facilities should be readily available for coping with any complication of the procedure, as well as for emergency treatment of severe reactions to the contrast agent itself (e.g. hypersensitivity, seizures).

The usual precaution for MRI examination should be taken, such as exclusion of patients with pacemakers, vascular clips, infusion pumps, nerve stimulators, cochlear implants, or suspected intracorporeal metallic foreign bodies, particularly in the eye.

#### **Hypersensitivity**

- Hypersensitivity reactions can occur, including life-threatening ones (see section 4.8). Hypersensitivity reactions may be either allergic (described as anaphylactic reactions when serious) or non-allergic. They can be either immediate (less than 60 minutes), or delayed (up to 7 days). Anaphylactic reactions can occur immediately and can be fatal. Hypersensitivity reactions may be independent of the dose, may occur after even the first dose of the product, and are often unpredictable.
- There is always a risk of hypersensitivity regardless of the dose injected.

- Patients who have already experienced a reaction during previous administration of a gadolinium-containing MRI contrast agent present an increased risk of experiencing another reaction on subsequent administration of the same product, or possibly other products, and are therefore considered to be at high risk.
- The injection of gadoteric acid may aggravate symptoms of an existing asthma. In patients with asthma unbalanced by the treatment, the decision to use gadoteric acid must be made after careful evaluation of the risk/benefit ratio.
- As known from the use of iodinated contrast media, hypersensitivity reactions can be aggravated in patients on beta-blockers, and particularly in the presence of bronchial asthma. These patients may be refractory to standard treatment of hypersensitivity reactions with beta-agonists.
- Before any contrast medium is injected, the patient should be questioned for a history of allergy (e.g. fish and seafood allergy, hay fever, hives), sensitivity to contrast media and bronchial asthma as the reported incidence of adverse reactions to contrast media is higher in patients with these conditions and premedication with antihistamines and/or glucocorticoids may be considered.
- During the examination, supervision by a physician is necessary. If hypersensitivity reactions occur, administration of the contrast medium must be discontinued immediately and, if necessary, specific therapy instituted. A venous access should thus be kept during the entire examination. To permit immediate emergency countermeasures, appropriate drugs (e.g. adrenaline and antihistamines), an endotracheal tube and a respirator should be ready at hand.

## Impaired renal function

Prior to administration of Clariscan it is recommended that all patients are screened for renal dysfunction by obtaining laboratory tests.

**There have been reports of nephrogenic systemic fibrosis (NSF) associated with use of some gadolinium-containing contrast agents in patients with acute or chronic severe renal impairment ( $\text{GFR} < 30 \text{ mL/min/1.73m}^2$ ). Patients undergoing liver transplantation are at particularly high risk since the incidence of acute renal failure is high in this group. As there is a possibility that NSF may occur with Clariscan, it should therefore only be used in patients with severe renal impairment and in patients in the perioperative liver transplantation period after careful risk/benefit assessment and if the diagnostic information is essential and not available with non-contrast enhanced MRI.**

Haemodialysis shortly after Clariscan administration may be useful at removing Clariscan from the body. There is no evidence to support the initiation of haemodialysis for prevention or treatment of NSF in patients not already undergoing haemodialysis.

## Elderly

As the renal clearance of gadoteric acid may be impaired in the elderly, it is particularly important to screen patients aged 65 years and older for renal dysfunction.

## Paediatric population

### Neonates and infants

Due to immature renal function in neonates up to 4 weeks of age and infants up to 1 year of age, Clariscan should only be used in these patients after careful consideration.

In neonates and infants, the required dose should be administered by hand.

## CNS disorders

Like with other gadolinium containing contrast agents special precaution is necessary in patients with a low threshold for seizures

Precautionary measures should be taken, e.g. close monitoring. All equipment and drugs necessary to counter any convulsions, which may occur, must be made ready for use beforehand.

## Cardiovascular disease

In patients with severe cardiovascular disease Clariscan should only be administered after careful benefit assessment because only limited data are available so far.

### **Patient preparation**

Nausea and vomiting are known possible undesirable effects when using MRI contrast agents. The patient should therefore refrain from eating for 2 hours prior to the investigation.

### **4.5 Interaction with other medicinal products and other forms of interaction**

No interactions with other medicinal products have been observed. Formal drug interaction studies have not been carried out.

Beta-blockers, vasoactive substances, angiotensin-converting enzyme inhibitors, angiotensin receptor antagonists: These medicinal products induce decreased efficacy of cardiovascular compensation mechanisms of blood pressure changes. The application of contrast media may increase the incidence of hypersensitivity reactions in patients taking beta-blockers (see section 4.4).

### **4.6 Fertility, pregnancy and lactation**

#### Pregnancy

Data on the use of gadolinium-based contrast agents including gadoteric acid in pregnant women is limited. Gadolinium can cross the placenta. It is unknown whether exposure to gadolinium is associated with adverse effects in the foetus. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3). Clariscan should not be used during pregnancy unless the clinical condition of the woman requires use of gadoteric acid.

#### Breastfeeding

Gadolinium containing contrast agents are excreted into breast milk in very small amounts (see section 5.3). At clinical doses, no effects on the infant are anticipated due to the small amount excreted in milk and poor absorption from the gut. Continuing or discontinuing breast feeding for a period of 24 hours after administration of Clariscan, should be at the discretion of the doctor and lactating mother.

#### Fertility

There are no clinical data available regarding the effects on fertility.

### **4.7 Effects on ability to drive and use machines**

No studies on the effects on the ability to drive and use machines have been performed. Ambulant patients while driving vehicles or operating machinery should take into account that nausea may incidentally occur.

### **4.8 Undesirable effects**

Side effects in association with the use of gadoteric acid are usually mild to moderate in intensity and transient in nature. Injection site reactions, nausea and headache are the most frequently observed reactions.

During clinical trials, nausea, headache, injection site reaction, feeling cold, hypotension, somnolence, dizziness, feeling hot, burning sensation, rash, asthenia, dysgeusia and hypertension were the most frequent, uncommonly observed ( $\geq 1/1000$  to  $< 1/100$ ), related adverse events..

Since post-marketing, the most commonly reported adverse reactions following administration of gadoteric acid are nausea, vomiting, pruritus and hypersensitivity reactions.

In hypersensitivity reactions, the reactions most frequently observed are skin reactions, which can be localized, extended or generalized.

These reactions occur most often immediately (during the injection or within one hour after the start of injection) or sometimes delayed (one hour to several days after injection), presenting as skin reactions in this case.

Immediate reactions include one or more effects, which appear simultaneously or sequentially, which are most often cutaneous, respiratory, gastrointestinal, articular and/or cardiovascular reactions. Each sign may be a warning sign of a starting shock and go very rarely to death.

Isolated cases of nephrogenic systemic fibrosis (NSF) have been reported with gadoteric acid, most of which were in patients co-administered other gadolinium-containing contrast agents (see section 4.4).

The adverse reactions are listed in the table below by SOC (System Organ Class) and by frequency with the following guidelines: very common ( $\geq 1/10$ ), common ( $\geq 1/100$  to  $< 1/10$ ), uncommon ( $\geq 1/1000$  to  $< 1/100$ ), rare ( $\geq 1/10\,000$  to  $< 1/1\,000$ ), very rare ( $< 1/10\,000$ ), not known (cannot be estimated from the available data). The data presented are from clinical trials involving 2822 patients when available, or from a pool of observational studies involving 185,500 patients.

| System Organ Class                                   | Frequency: adverse reaction   |
|--|---|
| Immune system disorders                              | Uncommon: hypersensitivity<br>Very rare: anaphylactic reaction, anaphylactoid reaction  |
| Psychiatric disorders                                | Rare: anxiety<br>Very rare: agitation   |
| Nervous system disorders                             | Uncommon: headache, dysgeusia, dizziness, somnolence, paraesthesia (including burning sensation)<br>Rare: presyncope<br>Very rare: coma, convulsion, syncope, parosmia, tremor  |
| Eye disorders  | Rare: eyelid oedema<br>Very rare: conjunctivitis, ocular hyperaemia, vision blurred, lacrimation increased  |
| Cardiac disorders                                    | Rare: palpitations<br>Very rare: cardiac arrest, bradycardia, tachycardia, arrhythmia   |
| Vascular disorders                                   | Uncommon: hypotension, hypertension<br>Very rare: vasodilatation, pallor  |
| Respiratory, thoracic and mediastinal disorders      | Rare: sneezing<br>Very rare: respiratory arrest, pulmonary oedema, bronchospasm, laryngospasm, pharyngeal oedema, dyspnoea, nasal congestion, cough, dry throat   |
| Gastrointestinal disorders                           | Uncommon: nausea, abdominal pain<br>Rare: vomiting, diarrhoea, salivary hypersecretion  |
| Skin and subcutaneous tissue disorders               | Uncommon: rash<br>Rare: urticaria, pruritus, hyperhidrosis<br>Very rare: erythema, eczema, angioedema<br>Not known: nephrogenic systemic fibrosis   |
| Musculoskeletal and connective tissue disorders      | Very rare: muscle cramps, muscular weakness, back pain  |
| General disorders and administration site conditions | Uncommon: feeling hot, feeling cold, asthenia, injection site reactions (pain, extravasation, discomfort, oedema, inflammation, coldness).<br>Rare: chest pain, chills<br>Very rare: malaise, chest discomfort, face oedema, pyrexia, injection site necrosis (in case of extravasation), superficial phlebitis |
| Investigations                                       | Very rare: decreased oxygen saturation  |

The following adverse reactions were reported with other intravenous contrast agents for MRI. It is therefore possible that they also occur during examination with Clariscan

| System Organ Class                   | Adverse reaction |
|--------------------------------------|------------------|
| Blood and lymphatic system disorders | Haemolysis       |
| Psychiatric disorders                | Confusion        |

|   |  |
|---|--|
| Eye disorders                                   | Blindness transient, eye pain  |
| Ear and labyrinth disorders                     | Tinnitus, ear pain   |
| Respiratory, thoracic and mediastinal disorders | Asthma   |
| Gastrointestinal disorders                      | Dry mouth  |
| Skin and subcutaneous tissue disorders          | Dermatitis bullous   |
| Renal and urinary disorders                     | Urinary incontinence, renal tubular necrosis, renal failure acute  |
| Investigations                                  | Electrocardiogram PR prolongation, blood iron increased, blood bilirubin increased, serum ferritin increased, liver function test abnormal |

### Adverse reaction in children

Safety of paediatric patients was considered in clinical trials and post marketing studies. As compared to adult, the safety profile of gadoteric acid did not show any specificity in children. Most of reactions are gastrointestinal symptoms or signs of hypersensitivity.

### Reporting of suspected adverse reactions:

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via HPRA Pharmacovigilance, Earlsfort Terrace, IRL - Dublin 2; Tel: +353 1 6764971; Fax: +353 1 6762517; Website: [www.hpra.ie](http://www.hpra.ie); E-mail: [medsafety@hpra.ie](mailto:medsafety@hpra.ie).

## 4.9 Overdose

Clariscan can be removed by haemodialysis. However, there is no evidence that haemodialysis is suitable for prevention of nephrogenic systemic fibrosis (NSF).

## 5 PHARMACOLOGICAL PROPERTIES

### 5.1 Pharmacodynamic properties

Pharmacotherapeutic group: paramagnetic contrast media

ATC code: V08 CA 02 (gadoteric acid)

This product has no specific pharmacodynamic activity.

Gadoteric acid is a paramagnetic agent for Magnetic Resonance Imaging (MRI). The contrast-enhancing effect is mediated by gadoteric acid which is an ionic gadolinium complex composed out of Gadolinium oxide and 1,4,7,10 tetraazacyclododecane-N,N',N'',N''' tetraacetic acid (DOTA), and present as meglumine salt.

The paramagnetic effect (relaxivity) is determined from the effect on spin-lattice relaxation time (T1) about  $3.4 \text{ mmol}^{-1} \cdot \text{L} \cdot \text{sec}^{-1}$  and on the spin-spin relaxation time (T2) about  $4.27 \text{ mmol}^{-1} \cdot \text{L} \cdot \text{sec}^{-1}$ .

### 5.2 Pharmacokinetic properties

#### Distribution

After intravenous injection, Clariscan is distributed in the extracellular fluids of the body. The distribution volume was approximately 18 L which is approximately equal to the volume of extra-cellular fluid. Gadoteric acid does not bind to proteins like serum albumin. Gadoteric acid is poorly excreted in the milk and crosses slowly through the placenta barrier.

#### Biotransformation

No metabolites were detected.

#### Elimination

Gadoteric acid is eliminated rapidly (89% after 6 h, 95% after 24 h) in unchanged form through the kidneys by glomerular filtration. Excretion via the faeces is negligible. The elimination half-life amounts to about 1.6 hours in patients with a normal renal function.

Special characteristics in patients with renal impairment

In renally impaired patients, the elimination half-life was increased to approximately 5 hours for a creatinine clearance between 30 and 60 mL/min and approximately 14 hours for a creatinine clearance between 10 and 30 mL/min.

**5.3 Preclinical safety data**

Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity or toxicity to reproduction.

Animal studies have shown negligible secretion (less than 1% of the dose) of gadoteric acid in maternal milk.

**6 PHARMACEUTICAL PARTICULARS****6.1 List of excipients**

Meglumine  
Tetraxetan (DOTA)  
Water for injections

**6.2 Incompatibilities**

In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.

**6.3 Shelf life**

3 years

**6.4 Special precautions for storage**

Do not freeze

**6.5 Nature and contents of container**

Clariscan is filled in the following containers:

Pre-filled syringes

Polymer syringe: Poly-cycloolefin, Crystal Clear Polymer (CCP) syringe of 20 mL (filled to 10, 15, and 20 mL), label graduated per mL with tip cap and halobutyl plunger stopper attached to a plunger rod.

Packed in outer box of 1 and 10 units.

Not all pack sizes may be marketed.

**6.6 Special precautions for disposal and other handling**

For single use

The solution for injection should be inspected visually prior to use. Only clear solutions free of visible particles should be used.

Prefilled syringes

Inject intravenously the quantity of product required for the examination.

The peel-off tracking label on the syringes should be stuck onto the patient record to enable accurate recording of the gadolinium contrast agent used. The dose used should also be recorded. If electronic patient records are used, the name of the product, the batch number and the dose should be entered into the patient record.



Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

**7 MARKETING AUTHORISATION HOLDER**

GE Healthcare AS  
P.O. Box 4220 Nydalen  
NO-0401 Oslo  
Norway

**8 MARKETING AUTHORISATION NUMBER**

PA0735/011/002

**9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION**

Date of first authorisation: 22<sup>nd</sup> December 2017

Date of last renewal: 24<sup>th</sup> January 2022

**10 DATE OF REVISION OF THE TEXT**

June 2024